|
gptkbp:instanceOf
|
alkaloid
antipsychotic medication
antihypertensive agent
|
|
gptkbp:ATCCode
|
C02AA05
|
|
gptkbp:brand
|
gptkb:Serpina
gptkb:Raudixin
gptkb:Serpasil
Sandril
|
|
gptkbp:CASNumber
|
50-55-5
|
|
gptkbp:category
|
World Health Organization essential medicine
|
|
gptkbp:chemicalFormula
|
C33H40N2O9
|
|
gptkbp:combines
|
gptkb:hydrochlorothiazide
other antihypertensives
hydralazine
|
|
gptkbp:contraindication
|
gptkb:depression
ulcerative colitis
electroconvulsive therapy
active peptic ulcer
|
|
gptkbp:derivedFrom
|
gptkb:Rauwolfia_serpentina
|
|
gptkbp:discoveredBy
|
1952
|
|
gptkbp:eliminationHalfLife
|
24–48 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:first_marketed
|
1954
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Reserpine
|
|
gptkbp:IUPACName
|
gptkb:methyl_(3β,16β,17α,18β,20α)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]_yohimban-16-carboxylate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
depletes monoamines from nerve endings
|
|
gptkbp:meltingPoint
|
265–266 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
608.7 g/mol
|
|
gptkbp:origin
|
plant-derived
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1379
5770
DB00206
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
nasal congestion
drowsiness
hypotension
bradycardia
gastrointestinal upset
|
|
gptkbp:solubility
|
insoluble in water
soluble in alcohol
soluble in chloroform
|
|
gptkbp:UNII
|
8B1QWR724A
|
|
gptkbp:usedFor
|
treatment of high blood pressure
treatment of psychotic states
|
|
gptkbp:bfsParent
|
gptkb:CIBA
|
|
gptkbp:bfsLayer
|
6
|